A Phase I–II Trial of Topotecan and Gemcitabine in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer (LOA-3)

REFERENCES

• Burris H. A., Fields S. F. Topoisomerase I Inhibitors: An Overview of Camptothecin Analogs. Hem. Oncol. Clin. North Am. 1994; 8(2)333–355
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Grochow L. B., Sartorius S. E., Bowling M. K., Kaufmann S. H., Peereboom D., Donehower R. C. Phase 1 and Pharmacologic Study of High Doses of the Topoisomerase I Inhibitor Topotecan with Granulocyte Colony-Stimulating Factor in Patients with Solid Tumors. J. Clin. Oncol. 1996; 14: 1224–1235
   PubMed Web of Science ®Google Scholar
• Budman D. R., Lichtman S. M. Investigational Drugs. The Chemotherapy Sourcebook, M. Perry. Williams and Wilkins, Baltimore 1997; 502–503
   Google Scholar
• Lynch T. J., Kalish L., Strauss G., Elias A., Skarin A., Shulman L. N., Posner M., Frei E. III. Phase II Study of Topotecan in Metastatic Non-Small-Cell Lung Cancer. J. Clin. Oncol. 1994; 12: 347–352
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Fossella F. V., Glisson B. S., Lee J. S., Murphy W. K., Shin D. M., Kemp B. L., Lee J. J., Kane J., Robinson R. A., Lippman S. M., Kurie J. M., Huber M. H., Raber M. N., Hong W. K. Phase II Study of Topotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Untreated with Chemotherapy. J. Clin. Oncol. 1996; 14: 503–513
   PubMed Web of Science ®Google Scholar
• White S. C., Cheeseman S., Anderson H., Thatcher N., Hearn S., Ross G., Ranson M. A Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer: Useful Symptom Palliation and 10 Month Median Survival. Proc. Am. Soc. Clin. Oncol 1999; abstract 2033
   Google Scholar
• Gutheil J., Kearns C. Antimetabolites. The Chemotherapy Sourcebook, M. Perry. Williams and Wilkins, Baltimore 1997; 323–325
   Google Scholar
• Eckardt J. R., Von Hoff D. D. New Drugs in Clinical Development in the United States. Hem. Oncol. Clin. North Am. 1994; 8(2)305–332
   PubMed Web of Science ®Google Scholar
• Hansen H. H., Sorensen J. B. Efficacy of Single-Agent Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Review. Semin. Oncol 1997; 24(suppl 7)38–41
   Google Scholar
• Rosell R., Tonato M., Sandler A. The Activity of Gemcitabine Plus Cisplatin in Randomized Trials in Untreated Patients with Advanced Non-Small Cell Lung Cancer. Semin. Oncol 1998; 25: 27–34
   PubMed Web of Science ®Google Scholar
• Dabrow M. B. The Lankenau Hospital Cancer Center, Wynnewood, PA. personal communication
   Google Scholar
• The WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva, Switzerland, 1979
   Google Scholar
• Dabrow M. B., Gilman P. B., Meyer T. J. Combined Therapy with Topotecan and Gemcitabine in Patients with Inoperable or Metastatic Non-Small Cell Lung Cancer. Proc. Am. Soc. Clin. Oncol 1999, abstract 1930
   Google Scholar
• Le Chevalier T., Gottfried M. Single-Agent Gemcitabine in Non-Small Cell Lung Cancer: The French Experience. Semin. Oncol 1997; 24: S7-47–S7-49
   Google Scholar
• Fukuoka M., Takada M., Yokoyama A., Kurita Y., Nitani H. Phase II Studies for Non-Small Cell Lung Cancer in Japan. Semin. Oncol 1997; 24: S7-420–S7-46
   Google Scholar
• Abratt R. P., Bezwoda W. R., Falkson G., Goedhals L., Hacking D., Rugg T. A. Efficacy and Safety Profile of Gemcitabine in Non-Small Cell Lung Cancer: A Phase II Study. J. Clin. Oncol 1994; 12: 1535–1540
   PubMed Web of Science ®Google Scholar
• Malayeri R., Ulsperger E., Baumgartner G., Forstner B., Aigner K., Hubner M., Kummer F., Krajnik G., Zochbauer S., Krejcy K., Huber H., Pirker R. Phase II Trial of Gemcitabine in Advanced Non-Small Cell Lung Cancer. Wien. Klin. Wochenschr 1997; 109: 688–691
   PubMed Web of Science ®Google Scholar
• Halme M., Jekunen A., Tamminen K., Mattson K. Phase II Study of Weekly Gemcitabine in Advanced Non- Small Cell Lung Cancer. Respir. Med. 1997; 91: 423–426
   PubMed Web of Science ®Google Scholar
• Gatzemeier U., Shepherd F. A., Le Chevalier T., Weynants P., Cottier B., Groen H. J., Rosso R., Mattson K., Cortes-Funes H., Tonato M., Burkes R. L., Gottfried M., Voi M. Activity of Gemcitabine in Patients with Non-Small Cell Lung Cancer: A Multicentre, Extended Phase II Study. Eur. J. Cancer 1996; 32: 243–248
   Web of Science ®Google Scholar
• Belani C. P. Single Agents in the Second-Line Treatment of Non-Small Cell Lung Cancer. Semin. Oncol 1998; 25: 10–14
   PubMed Web of Science ®Google Scholar
• Rosvold E., Langer C. J., Schilder R., Millenson M., Reimet E., Kreamer K. Salvage Therapy with Gemcitab-ine in Advanced Non-Small Cell Lung Cancer (NSCLC) Progressing After Prior Carboplatin-Paclitaxel (C-P). Proc. Am. Soc. Clin. Oncol 1998, abstract 1797
   Google Scholar
• Crino L., Mosconi A. M., Scagliotti G. V., Selvaggi G., Rinaldi M., Della Giulia M., Gridelli C., Calandri C., De Marinis F., Noseda M., Tonato M. Gemcitabine as a Second-Line Treatment for Relapsing or Refractory Advanced non-Small Cell Lung Cancer: A Phase II Trial. Semin. Oncol 1998; 25: 23–26
   PubMed Web of Science ®Google Scholar
• Garfield D. H., Dakhil S. R., Whittaker T. L., Keller A. M. Phase II Randomized Multicenter Trial of Two Dose Schedules of Gemcitabine as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC). Proc. Am. Soc. Clin. Oncol 1998, abstract 1863
   Google Scholar
• Androulakis N., Papadakis E., Bania E., Apostolopulou F., Tsiafaki X., Kalofonos C., Rapti A., Toubis M., Chainis K., Kouroussis Ch., Sarra E., Vardakis N., Hatzidaki D., Georgoulias V. Second Line Treatment with Docetaxel (d) and Gemcitabine (G) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial. Proc. Am. Soc. Clin. Oncol 1999, abstract 1907
   PubMedGoogle Scholar
• Georgoulias V., Kourousis C., Kakolyris S., Androulakis N., Dimopoulos M. A., Papadakis E., Kotsakis T., Vardakis N., Kalbakis K., Merambeliotakis N., Hatzidaki D. Second-Line Treatment of Advanced Non-Small Cell Lung Cancer with Paclitaxel and Gemcitabine: A Preliminary Report on an Active Regimen. Semin. Oncol 1997; 24: S12-61–S12-66
   Web of Science ®Google Scholar
• Gian V., Hainsworth J. H., Burris H. A., Erland J. B., Brown C. P., Rinaldi D. A., Greco F. A. Combination Gemcitabine and Vinorelbine in the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase II Study of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol 1999; 18: 1949
   Google Scholar